Acadia Opening Phase 2/3 Trial of Trofinetide in Young Girls, 2-5

Acadia Opening Phase 2/3 Trial of Trofinetide in Young Girls, 2-5

305064

Acadia Opening Phase 2/3 Trial of Trofinetide in Young Girls, 2-5

Acadia Pharmaceuticals is launching an open-label clinical trial of its oral investigational medication trofinetide in toddlers and young girls with Rett syndrome, the company announced in a letter to the Rett community. The 12-week Phase 2/3 trial, called DAFFODIL (NCT04988867), aims to enroll about 10 children, ages 2 to 5. All study participants will be treated with 10–30 mL of trofinetide solution twice daily, with doses based on an individual’s weight. Its main goal is to assess the…

You must be logged in to read/download the full post.